Meeting
2021 ASCO Annual Meeting
Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.
Authors
Michael S. Gordon
HonorHealth Research Institute, Scottsdale, AZ
Michael S. Gordon , Richard D. Carvajal , Alexander I. Spira , Marilyn Huang , Paul Watkins , Ben Powell , Kerry Inokuchi , Michael Sterba , Bernice Matusow , Chelsea Hope , Jason Halladay , Chao Zhang , Jacqueline M. Walling , Athanasios C. Tsiatis , Amita Patnaik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03297424
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3018)
DOI
10.1200/JCO.2021.39.15_suppl.3018
Abstract #
3018
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.
First Author: Hendrik-Tobias Arkenau
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.
First Author: Shunsuke Kondo
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George
Poster
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
First Author: Xing Zhang